Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Authors
Javed, MBeyer, G
Le, N
Vinci, A
Wong, H
Palmer, D
Morgan, Robert David
Lamarca, Angela
Hubner, Richard A
Valle, Juan W
Alam, S
Chowdhury, S
Ma, Y
Archibugi, L
Capurso, G
Maisonneuve, P
Neesse, A
Sund, M
Schober, M
Krug, S
Affiliation
NIHR Liverpool Pancreas Biomedical Research Unit, Institute of Translational Medicine, Royal Liverpool University Hospital, United KingdomIssue Date
2018
Metadata
Show full item recordAbstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma (MPA). Randomized clinical trials evaluating intensified chemotherapies including FOLFIRINOX and nab-paclitaxel plus gemcitabine (NAB+GEM) have shown improvement in survival. Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe. METHODS: A retrospective multi-center study including 1056 MPA patients, between 2012 and 2015, from nine centers in UK, Germany, Italy, Hungary and the Swedish registry was performed. Follow-up was at least 12 months. Cox proportional Harzards regression was used for uni- and multivariable evaluation of prognostic factors. RESULTS: Of 1056 MPA patients, 1030 (98.7%) were assessable for survival analysis. Gemcitabine monotherapy was the most commonly used regimen (41.3%), compared to FOLFIRINOX (n = 204, 19.3%), NAB+GEM (n = 81, 7.7%) and other gemcitabine- or 5-FU-based regimens (n = 335, 31.7%). The median overall survival (OS) was: FOLFIRINOX 9.9 months (95%CI 8.4-12.6), NAB+GEM 7.9 months (95%CI 6.2-10.0), other combinations 8.5 months (95%CI 7.7-9.3) and gemcitabine monotherapy 4.9 months (95%CI 4.4-5.6). Compared to gemcitabine monotherapy, any combination of chemotherapeutics improved the survival with no significant difference between the intensified regimens. Multivariable analysis showed an association between treatment center, male gender, inoperability at diagnosis and performance status (ECOG 1-3) with poor prognosis. CONCLUSION: Gemcitabine monotherapy was predominantly used in 2012-2015. Intensified chemotherapy improved OS in comparison to gemcitabine monotherapy. In real-life settings, the OS rates of different treatment approaches are lower than shown in randomized phase III trials.Citation
Javed M, Beyer G, Le N, Vinci A, Wong H, Palmer D, et al. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2018 Oct 15.Journal
PancreatologyDOI
10.1016/j.pan.2018.10.003PubMed ID
30529068Additional Links
https://dx.doi.org/10.1016/j.pan.2018.10.003Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.pan.2018.10.003
Scopus Count
Collections
Related articles
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
- Authors: Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N, TPK-Group (Tumour Registry Pancreatic Cancer)
- Issue date: 2019 Mar 1
- Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
- Authors: Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, Homs MYV, van Laarhoven HWM, Molenaar IQ, Ten Tije BJ, de Vos-Geelen J, Besselink MG, van der Geest LGM, Wilmink JW, Dutch Pancreatic Cancer Group
- Issue date: 2020 Jun
- Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
- Authors: Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S
- Issue date: 2019 May 17
- FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
- Authors: Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M, TPK-Group (Tumour Registry Pancreatic Cancer)
- Issue date: 2023 Feb 1
- First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
- Authors: Pijnappel EN, Dijksterhuis WPM, van der Geest LG, de Vos-Geelen J, de Groot JWB, Homs MYV, Creemers GJ, Mohammad NH, Besselink MG, van Laarhoven HWM, Wilmink JW, Dutch Pancreatic Cancer Group
- Issue date: 2021 Aug 27